Leadership Overview
Lonza has 5 executives leading key functions including strategy, finance, operations, and regional management.
Driven by innovation, Lonza provides essential services and products across pharmaceutical, biotech, and specialty ingredients markets, advancing global health and addressing critical pathogen control.
Driven by innovation, Lonza provides essential services and products across pharmaceutical, biotech, and specialty ingredients markets, advancing global health and addressing critical pathogen control.
Leadership Roles at Lonza
Robert Whitelaw - President & Chief Executive Officer (Japan)
Robert Whitelaw, the President & Chief Executive Officer (Japan) at Lonza, spearheads the company's strategic direction and operational execution within the Japanese market. This leadership role encompasses driving business development, managing regional P&L, and ensuring alignment with Lonza's global objectives in serving the pharmaceutical, biotech, and specialty ingredients sectors. Whitelaw oversees the expansion of services and products, including active pharmaceutical ingredients and microbial control technologies, tailored to regional demands. The President & Chief Executive Officer (Japan) fosters key relationships with local partners and stakeholders, navigating the unique business landscape to maximize market penetration and revenue growth. By championing Lonza's commitment to innovation and global health, Robert Whitelaw ensures robust performance and strategic positioning within Japan.
Mary Lucero - Chief Financial Officer
Mary Lucero, the Chief Financial Officer at Lonza, oversees all financial operations and strategic financial planning for the global enterprise. This critical position involves managing capital allocation, financial reporting, and investor relations, ensuring fiscal health and driving sustainable growth across Lonza's diverse market segments. Lucero's responsibilities extend to optimizing financial performance for both the Pharma & Biotech and Specialty Ingredients divisions, supporting the development and delivery of products like active pharmaceutical ingredients and nutritional ingredients. The Chief Financial Officer plays a pivotal role in evaluating investment opportunities and managing financial risks, thereby safeguarding the company's assets and enhancing shareholder value. Through rigorous financial oversight, Mary Lucero directly supports Lonza's mission of innovation and its impact on global health and industrial preservation.
Marcello Giora - Region General Manager & Chief Financial Officer (South America)
Marcello Giora, the Region General Manager & Chief Financial Officer (South America) at Lonza, directs both the overall business strategy and financial management for the South American region. This dual mandate involves overseeing operational expansion, driving revenue growth, and ensuring fiscal discipline across Lonza's diverse product and service offerings in the region, including pharmaceutical ingredients and industrial preservatives. Giora's financial acumen supports strategic investments and resource allocation, optimizing profitability and market share within South America. The Region General Manager & Chief Financial Officer (South America) also leads market-specific initiatives, adapting Lonza's global portfolio to meet local needs and regulatory requirements. Through this comprehensive leadership, Marcello Giora significantly contributes to Lonza's global presence and its mission to advance health and safety.
Margaret McDonald - Executive Vice President & Chief Financial Officer
Margaret McDonald, the Executive Vice President & Chief Financial Officer at Lonza, provides overarching financial leadership and strategic fiscal direction for the entire global organization. This executive role involves shaping financial policy, managing corporate finance, and driving key financial strategies that support Lonza's mission across the pharmaceutical, biotech, and specialty ingredients markets. McDonald's oversight extends to optimizing financial performance, ensuring robust capital management, and guiding investment decisions for critical areas such as active pharmaceutical ingredients and microbial control technologies. The Executive Vice President & Chief Financial Officer collaborates closely with other C-suite leaders to align financial objectives with operational goals, thereby enhancing efficiency and fostering sustainable growth. Through expert financial stewardship, Margaret McDonald ensures Lonza's continued innovation and its vital contribution to global health and industrial solutions.
Jean-Paul Ouellette - Chief of Staff
Jean-Paul Ouellette, the Chief of Staff at Lonza, directs strategic initiatives and operational alignment across the organization. This role involves translating high-level corporate objectives into actionable plans, ensuring seamless execution of the company's mission to serve pharmaceutical, biotech, and specialty ingredients markets. Ouellette coordinates cross-functional teams to optimize service and product delivery, including active pharmaceutical ingredients and microbial control technologies. The Chief of Staff facilitates communication between executive leadership and various departments, driving efficiency and fostering a cohesive operational environment. By managing key projects and advising executive decision-making, Jean-Paul Ouellette ensures Lonza's strategic priorities are met, contributing directly to the company's commitment to innovation and global health advancement.
Explore Leadership Teams in Manufacturing
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad, deep-scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred Contract Development and Manufacturing Organization (CDMO) partner for personalized medicines, blockbuster drugs and consumer health brand extensions.
Company Leadership
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership TI
SG
SP
CS
Dexcel Pharma is Israel’s largest privately owned pharmaceutical company, founded in 1968 and headquartered in Or Akiva. It develops, manufactures, and commercializes value‑added branded prescription drugs, generics, and OTC products—primarily oral solid dosage forms—supplying more than 85 products in over 175 dosage forms to markets including the U.S., U.K., Germany, Austria, and others through subsidiaries and distribution partners.
Company Leadership
UE
EH
Founded in 1891, Adcock Ingram is a pharmaceutical manufacturer headquartered in Gauteng, South Africa. Adcock Ingram manufactures, markets and distributes a range of healthcare products.
Company Leadership AH
WR
FC
GH
Frequently Asked Questions Regarding Lonza Top Executives and Leadership Team
